Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns

Clin Infect Dis. 2023 Aug 22;77(4):583-588. doi: 10.1093/cid/ciad248.

Authors

Naomi E Aronson¹, Kendall Billick²

Affiliations

¹ Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
² Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.

PMID: 37185765
DOI: 10.1093/cid/ciad248

No abstract available

Publication types

Comment

MeSH terms

Antiprotozoal Agents* / therapeutic use
Brazil
Humans
Leishmania braziliensis*
Leishmaniasis, Cutaneous* / drug therapy
Meglumine Antimoniate / therapeutic use

Substances

Meglumine Antimoniate
Antiprotozoal Agents